The ARID5A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, with disruption of the ARID5A gene. This loss-of-function model utilizes CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of edited alleles that ablate ARID5A protein expression. Intended for post-transcriptional gene regulation studies, this polyclonal format avoids clonal bias and is well-suited for investigating mRNA stability and inflammatory signaling.
The HeLa host cell line is an HPV18-positive cervical adenocarcinoma epithelial line, widely employed in cancer biology and virology. Viral E6 and E7 oncoproteins inactivate p53 and Rb, leading to aneuploidy and rapid proliferation. These features provide a robust platform for examining gene function in an epithelial context, including the interplay between viral transformation and host post-transcriptional control.
ARID5A is a nucleic acid-binding protein that stabilizes AU-rich element (ARE)-containing mRNAs, particularly those encoding pro-inflammatory cytokines like IL-6, IL-1??, and TNF-??. Upstream, TLR4 ligands (e.g., LPS) and cytokines activate NF-??B, promoting ARID5A expression. ARID5A then binds AREs in target mRNA 3??UTRs, interacting with UPF1 and the exosome complex to prevent degradation, thereby enhancing mRNA half-life. This augments cytokine output and drives IL-6/STAT3 signaling, with downstream effectors including SOCS3 and IRE1??, linking ARID5A to stress and immune responses.
In HeLa cells, ARID5A knockout reduces stabilization of pro-inflammatory transcripts, dampening downstream cytokine production. This model enables dissection of ARID5A-dependent post-transcriptional regulation independently of HPV-mediated p53/Rb inactivation. Upon stimulation with inflammatory agonists, the cells allow measurement of cytokine mRNA decay and secretion, making them valuable for research on chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, obesity, and multiple sclerosis.
Applications include western blotting for ARID5A and IL-6, RT-qPCR for cytokine mRNAs, and ELISA for secreted cytokines. RNA stability assays (e.g., actinomycin D chase) and luciferase reporters with AREs quantitatively assess mRNA stabilization. Co-immunoprecipitation detects ARID5A?CmRNA complexes and interactions with factors like UPF1. This polyclonal knockout platform supports screening of ARE-mediated decay modulators and therapeutic target evaluation. For further information, contact Ascent Research.
